Member Info for TRENCH123

The market reaction to the proposed merger between EUDA and Theoremrx has been interesting

THE EUDA share price on the day before the announcement was in the range $1.53-$1.55 and rallied following the announcement peaking at $1.93-$2.02 on 12th October. Since then it has fallen and is now in the range $0.80-$0.86

Is this a pointer as to whether the deal will go through. Time will tell. I see this as a 50%:50% call

Started investing here in Mark Chadwick days and been here almost continuously ever since. Sold out at c 4p when the big spike happened and bought back in some months later. Have just short of 1 million shares here

Have enjoyed observing the chat from the sidelines until recently

Every reason to think it will recover. JM assembling a top team with some exciting initiatives going on behind the scenes

Reasons for poor performance last year well documented. Outlook much better

Why if the merger document is so exciting is the price down 8% today ?

The 50% headroom request looks like standard policy for the company. Exactly the same wording was included in the 2022, 2021 and 2020 AGM resolutions, albeit we now have more share in issue

I suspect quite a number of PYC investors will have sold some or all of their holdings and moved into Valirx where positive news is anticipated, hence the drift in the PYC share price

The money will return if PYC can come up with some exciting news. I am looking forward to hearing news on the bio-statistics initiative

The Guardian article is quite relevant to the work PYC are involved in with regards to DNA damage and repair (DDR) and obtaining maximum benefit from existing drugs

PYC are involved with Merck on DNA-related work and in the RNS of 13th December 2021 Jim Millen comments ' In our view, there is no other company with Physiomics' experience in the field of DDR modelling and with every new project we further develop our capabilities in this field'

The PYC newsletter contained an article written by PYC employees/consultants with reference to personalised dosing, In it they comment 'While the quest for new drugs is of course essential, an alternative and much less expensive approach to improving outcomes is to use existing drugs more efficiently, concentrating on questions such as dosage and timing. There is increasing evidence that drugs can have a very different effect depending on the details of how and when they are taken, and on who they are taken by; and unlike the design of a radical new compound, such questions are often amenable to analysis using mathematical models.'

Interesting that Dosemerx were also attending a conference in Boston at same time as Physiomics - theirs at IDWeek2023 (from 11-15 October) where they were promoting their latest innovations in Precision Dosing

It would appear that Dosemerx are still in discussions with PYC reference the Docetaxel precision dosing tool. Surely we must be close to an update on this

Physiomics tweeted ref the Ankyra-Merck collaboration and supply agreement to assess ANK-101 over a week ago

Extract from EUDA announcement of potential merger with TheoremRx :

We believe TheoremRx has strong access to capital and a robust pipeline of compounds addressing high-demand unmet therapeutic areas with NEAR-TERM inflection points. Its project portfolio is also pre-selected for high upside, with MINIMAL TIME AND COST to reach key monetization milestones.

I have highlighted in bold some key words from the announcement. I was under the impression that VAL201 had not progressed to Stage 2 trials yet and the initial results, extremely promising though they were, were based on only a handful of patients. More expansive, costly and time-consuming trials would clearly be necessary before any clarity of outcome can be determined

Do we think the statement relates predominantly to VAL201. If so, why the inappropriate wording ?

Unsurprising that Jim Millen has chosen not to hold an Investor Meet Company presentation following the release of the very poor results to June 2023. Would have been a hard task to put a positive spin on the record losses

More likely waiting until he has some good news to impart - Precision Dosing Tool update or Beyond Blood grant news perhaps - before announcing a presentation. The first newsletter, yet to be issued, would also have more impact with a major news item to discuss

Tweet from PYC earlier today to advise they are presenting a poster at the AACR International Conference on 12th October reference their Ankyra collaboration

I like the comment in the tweet ' Come and join us and see how Physiomics is ''transforming cancer drug development'' also the recent initiation of a company newsletter. Suggests an underlying confidence which I have not noted before

The results we are awaiting are not the Interims but the Full year results to 30th June, 2023. The narrative on the RNS header last September was incorrect. Normally with the Full year results a prior RNS will announce the date of publication of the results

Not expecting the figures to be good with the reduced turnover arising from delayed work. The outlook for the year to 30th June, 2024 is likely to be much more interesting

On 28th March 2023 PYC announced a collaboration agreement with Beyond Blood Diagnostics, a company designing a small device for measuring blood cell counts away from traditional hospital settings. Under the agreement PYC are to carry out analysis of the data generated by the device using its personalised dosing software

The CEO of Beyond Blood discusses his company on a Connectd platform release made in April 2023. He comments :-

The growth plan is obviously we are high-tech and deep-tech, is really growing the company as fast as we can. We have tripled the valuation in the first eight months. We're now 10 million valuation and we are planning on having a 33 million valuation in the next 12 months. This is possible only through people, through doors and connections that you need to build as a founder. So that's the plan for next year. We are planning to have a first prototype of the device that can be mass-produced by the end of next year, and this will be achieved through a first partnership that we have at the moment with a public company * that has been established a month ago and it has been announced in the London Stock Exchange News as well.

Jim Millen refers to the collaboration in the latest PYC Investor Meet Company presentation. He believes the device could be helpful in relation to the development of the personalised dosing and is looking into whether there were ‘significant’ grants available in this area

It will be interesting to see whether we get an update on the collaboration in the presentation accompanying the release of the final results which are due shortly

* = PYC

I note that PYC have a Digital Performance Director (Consultant) - Ken Ung. He appears to be also working as Pfizer UK Digital Lead (oncology)

I don't have access to Ken Ung's Linkedin account, but anyone with access should be able to find more details about him